Bayer, Huma team up on AI for lung cancer

By staff writers

September 30, 2021 -- Bayer and U.K.-based artificial intelligence (AI) software developer Huma are joining forces to develop AI technology to distinguish different forms of non-small-cell lung cancer (NSCLC) on CT exams.

Making use of Huma's machine-learning experience and Bayer's oncology and medical imaging capabilities, the companies plan to utilize machine-learning technology to spot correlations in molecular and imaging assessments -- such as ground-glass opacities -- that can differentiate types of lung cancers. They will then train and test models to provide accurate diagnoses.

The goal is to quickly identify the patients with certain types of NSCLC who can benefit the most from tailored treatments, according to the firms. Their collaboration will begin immediately.

Bayer's Leaps by Bayer investment arm has been both a series B and series C investor in Huma.

Copyright © 2021

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking